Szturmowicz Monika, Kacprzak Aneta, Szołkowska Małgorzata, Burakowska Barbara, Szczepulska Ewa, Kuś Jan
1st Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
Adv Respir Med. 2018;86(3). doi: 10.5603/ARM.2018.0021.
Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary haemangiomatosis (PCH) are rare disorders, with the estimated prevalence of less than 1 case per million inhabitants. The vascular pathology in PVOD/PCH involves pre-septal and septal veins, alveolar capillaries and small pulmonary arteries. According to the ERS/ESC classification of pulmonary hypertension (PH) from 2015, PVOD/PCH have been included in the subgroup 1' of pulmonary arterial hypertension (PAH). Recent data indicate, however, the possibility of PVOD/PCH pathology in the patients diagnosed in the group 1. The problem may concern PAH associated with scleroderma, drug- induced PAH, PAH due to HIV infection and up to 10% of patients with idiopathic PAH (IPAH). Recently, bi-allelic EIF2AK4 mutations were found in the cases with heritable form of PVOD/PCH and in about 9% of sporadic cases. Moreover, an association between occupational exposure to organic solvents and PVOD/PCH was proved. The present review is an attempt to summarise the current data on pathogenesis, risk factors, clinical features and diagnostic algorithm for PVOD/PCH.
肺静脉闭塞性疾病(PVOD)和肺毛细血管瘤病(PCH)是罕见疾病,估计每百万居民中患病率低于1例。PVOD/PCH的血管病理涉及小叶前和小叶间隔静脉、肺泡毛细血管和小肺动脉。根据2015年欧洲呼吸学会/欧洲心脏病学会肺动脉高压(PH)分类,PVOD/PCH已被纳入肺动脉高压(PAH)的1'亚组。然而,最近的数据表明,在诊断为1组的患者中存在PVOD/PCH病理的可能性。这个问题可能涉及与硬皮病相关的PAH、药物性PAH、HIV感染所致的PAH以及高达10%的特发性PAH(IPAH)患者。最近,在遗传性PVOD/PCH病例以及约9%的散发性病例中发现了双等位基因EIF2AK4突变。此外,已证实职业性接触有机溶剂与PVOD/PCH之间存在关联。本综述旨在总结目前关于PVOD/PCH的发病机制、危险因素、临床特征和诊断算法的数据。